WO2019194738A1 - Nouvelles associations d'un inhibiteur de polymérisation de la tubuline et d'un inhibiteur de la poly(adp-ribose) polymérase (parp) destinées à être utilisées dans le traitement du cancer - Google Patents

Nouvelles associations d'un inhibiteur de polymérisation de la tubuline et d'un inhibiteur de la poly(adp-ribose) polymérase (parp) destinées à être utilisées dans le traitement du cancer Download PDF

Info

Publication number
WO2019194738A1
WO2019194738A1 PCT/SE2019/050312 SE2019050312W WO2019194738A1 WO 2019194738 A1 WO2019194738 A1 WO 2019194738A1 SE 2019050312 W SE2019050312 W SE 2019050312W WO 2019194738 A1 WO2019194738 A1 WO 2019194738A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
indol
combination
inhibitor
methyl
Prior art date
Application number
PCT/SE2019/050312
Other languages
English (en)
Inventor
Marita Högberg
Stefan Rehnmark
Original Assignee
Noviga Research Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noviga Research Ab filed Critical Noviga Research Ab
Priority to EP19781419.7A priority Critical patent/EP3773592A4/fr
Priority to US16/981,232 priority patent/US11590130B2/en
Priority to JP2020551269A priority patent/JP7372253B2/ja
Priority to CN201980024687.3A priority patent/CN111936143A/zh
Priority to CA3095709A priority patent/CA3095709A1/fr
Publication of WO2019194738A1 publication Critical patent/WO2019194738A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • Methods and combination therapies for treating, preventing, and/or delaying the onset and/or development of cancer using a compound of formula I or a pharmaceutically acceptable salt thereof, and a poly (ADP-ribose) polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt thereof, are provided.
  • Cancer is a phrase used describing a wide variety of diseases that are each characterized by the uncontrolled growth of a particular type of cell. It begins in a tissue containing such a cell and, if the cancer has not spread to any additional tissues at the time of diagnosis, may be treated by, for example, surgery, radiation, or another type of localized therapy.
  • different approaches to treatment are typically used. Indeed, because it is not possible to determine with certainty the extent of metastasis, systemic approaches to therapy are usually undertaken when any evidence of spread is detected. These approaches involve the administration of, for example, chemotherapeutic drugs that interfere with the growth of rapidly dividing cells, such as cancer cells.
  • Other approaches involve the use of immunotherapy, in which an immune response against cancerous cells in a subject is elicited or enhanced.
  • Ovarian cancer is caused by uncontrollable cell growth in the ovarian tissue and epithelial OC accounts for 90% of all OCs.
  • OC is the seventh most common cancer in women worldwide, with nearly a quarter of a million women diagnosed with it each year. Responsible for approximately 140,000 deaths per annum, this cancer has the highest mortality rate of all gynaecological cancers. Staggering statistics show that only 45% of women with OC are likely to survive for five years compared to up to 89% of women with breast cancer.
  • One of the biggest challenges facing ovarian cancer treatment is the late stage (III and IV) diagnosis due to nonspecific symptoms and lack of simple, routine tests for screening of the disease.
  • OC is a silent disease that usually is diagnosed at a late stage, and around 75% of the patients are diagnosed at an advanced-stage (stage III and IV).
  • stage III and IV advanced-stage
  • the combination of carboplatin and paclitaxel given every 3 weeks remains the standard first line chemotherapy for OC.
  • resistance to the first line chemotherapy is common in patients with advanced disease and around 80% of the patients with stage III or IV disease will relapse after first line combination chemotherapy.
  • There is considerable heterogeneity with regard to overall drug sensitivity but patients with recurrent OC eventually develop platinum- and/or platinum/paclitaxel - resistant disease.
  • Current second line therapy to resistant/refractory OC is dependent on resistance mechanisms and different combinations of different cytotoxic agents, targeted agents and anti angiogenesis biologic drugs are being used with limited therapeutic efficacy.
  • the relative 5 years survival is poor, especially for women diagnosed with advanced disease.
  • Microtubules are important components of the cytoskeleton of eukaryotic cells and have an important role in various cellular functions, such as cell signaling and mitosis. It is a validated drug target in oncology and there are approved anti-cancer drugs on the market targeting microtubules (e.g. paclitaxel, vincristine, sagopilone).
  • Tubulin targeting compounds are characterized by their binding to tubulin and their effects on tubulin polymerization. The compounds exhibit their anticancer properties by interfering with the dynamics of tubulin resulting in mitotic arrest.
  • tubulin targeting compounds There are two classes of tubulin targeting compounds: i) inhibitors of tubulin depolymerization (e.g.
  • tubulin polymerization e.g. colchicine, combretastatin, vincristine and vinblastine.
  • colchicine combretastatin, vincristine and vinblastine.
  • the tubulin-binding site has been described for its ability to bind a naturally occurring tricyclic alkaloid colchicine, which inhibits tubulin polymerization.
  • Colchicine itself is not a useful anticancer agent because of its narrow therapeutic window, but compounds with diverse chemical structures that bind to this site or near are now in clinical or preclinical developments e.g.
  • combretastatin CA-4P (zybrestat), AVE-8062 (ombrabulin), BNC105P, MPC-6827 (azixa), ZD6126 (ANG453), Oxi- 4503, BPI-2358 (plinabulin), MN029 (denibulin), EPC-2407 (crinobulin), ZIO-301 (indibulin), T115, BPR0L075, ABT-751.
  • tubulin polymerization inhibitors are well described in the literature, e.g. in WO2011/151423, and in European J. Med. Chem., 87(2014) 89-124 which are hereby incorporated by reference.
  • Plinabulin (BPI-2358) is a small molecule currently undergoing clinical development for treating cancer, primarily non-small cell lung cancer. Plinabulin selectively binds to tubulin monomers and thereby prevents the polymerization of tubulin. Plinabulin is a chemical compound having the structure:
  • First line therapy for patients with epithelial OC is a combination of a tubulin inhibitor drug (e.g. paclitaxel) and a DNA cross-linking (platinum) drug (e.g. carboplatin, cisplatin).
  • Paclitaxel suppresses tumour cell proliferation by inhibiting tubulin depolymerisation.
  • the cytotoxic activity of platinum compounds is mediated through its binding with DNA and the production of intra- and inter-strand crosslinks, as well as the formation of adducts that cause conformational changes in DNA. This subsequently impairs replication and inhibits DNA synthesis leading to cell death.
  • a tubulin inhibitor drug e.g. paclitaxel
  • platinumum DNA cross-linking
  • Second line therapy Current second line therapy to refractory OC is dependent on resistance mechanisms and different combinations of different cytotoxic agents, targeted agents and anti angiogenesis biologic drugs (e.g. gemcitabine, bevacizumab, etopside, olaparib (PARP inhibitor), topotecan and doxorubicine) are being used with limited therapeutic efficacy.
  • cytotoxic agents e.g. gemcitabine, bevacizumab, etopside, olaparib (PARP inhibitor), topotecan and doxorubicine
  • PARP inhibitor olaparib
  • topotecan doxorubicine
  • the present invention relates to methods of treating, preventing or alleviating cancer, comprising administering to a subject in need thereof (i) a therapeutically effective amount of a tubulin polymerization inhibitor or a pharmaceutically acceptable salt, hydrate, solvate or amorphous solid thereof, and (ii) a therapeutically effective amount of a poly (ADP-ribose) polymerase (PARP) inhibitor or a pharmaceutically acceptable salt, hydrate, solvate or amorphous solid thereof.
  • PARP poly (ADP-ribose) polymerase
  • the tubulin polymerization inhibitor is a compound of formula I, or a pharmaceutically acceptable solvate or salt thereof.
  • the present invention relates to methods of treating, preventing or alleviating cancer, comprising administering to a subject in need thereof (i) a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable solvate or salt thereof, and (ii) a therapeutically effective amount of a poly (ADP-ribose) polymerase (PARP) inhibitor or a pharmaceutically acceptable salt, hydrate, solvate or amorphous solid thereof.
  • PARP poly (ADP-ribose) polymerase
  • the invention provides a compound of formula I, or a pharmaceutically acceptable solvate or salt thereof, and a poly (ADP-ribose) polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate or amorphous solid thereof, in combination, for use in treatment of cancer;
  • PARP poly (ADP-ribose) polymerase
  • R 1 , R 3 , R 8 , R 12 , R 13 , and R 14 represent hydrogen
  • R 2 represents hydrogen or methyl
  • R 4 , R 5 , R 6 , and R 7 are independently selected from hydrogen, halogen, hydroxy, (CrC 4 )alkyl, 0(CrC4)alkyl, 0(Ci-C4)alkyl(C2-C5)heterocyclyl, and OCF 3 ;
  • R 10 is selected from hydrogen, (CrC 4 )alkyl and Nhh;
  • R 1 1 is selected from hydrogen, (CrC 4 )alkyl, (CO)NH 2 , and (C 2 -C 5 )heterocyclyl(Ci-C 4 )alkyl;
  • R 9 is selected from:
  • R 15 is selected from hydrogen and methyl
  • R 16 and R 17 are independently selected from hydrogen, (CrC4)alkyl, (Ci-C4)alkyl-OH, and (CO)OH.
  • said compound of formula I is selected from:
  • A/ 2 [2-(5-methoxy-1 /-/-indol-3-yl)ethyl]-5-methyl-A/ 4 -(2-methyl-1 /-/-indol-5-yl)pyrimidine-2,4- diamine;
  • said compound of formula I is A/ 2 -[2-(5-methoxy-1 H-indol-3-yl)ethyl]-/ ⁇ / 4 -(1- methyl-1 H-indol-4-yl)pyrimidine-2, 4-diamine (NOV202).
  • NOV202 is a chemical compound with the following structure:
  • NOV202 has the following IUPAC nomenclature: N 2 -[2-(5-methoxy-1 H-indol-3-yl)ethyl]-N 4 -(1- methyl-1 H-indol-4-yl)pyrimidine-2, 4-diamine. Its structure and antitumor effects have been described in inter alia Rickardson et al. , Drug Design, Development and Therapy 2017: 1 1 , 1335-1351 and WO 2012/127032. Methods of synthesizing compounds of Formula I, including NOV202, are described in WO 2012/127032.
  • NOV202 has been shown to have potent anti-proliferative activity in a panel of human cancer cell lines, including both solid and hematological
  • NOV202 has also been shown to be as effective in multidrug resistant OC cells as in the isogenic (drug sensitive variant) non-resistant OC cells.
  • the A2780/Adr multidrug resistant OC cell line overexpresses the P-glycoprotein efflux transporters which confer multidrug resistance.
  • NOV202 was also shown to be highly potent in causing cell death, indicating that NOV202 could be a potential therapy for women that relapse after first-line therapy of OC.
  • tumour vasculature targeting agents in anti cancer therapy is that the cancer cells will be deprived of essential nutrients and oxygen supply for their growth and spread, thereby improving treatment outcome.
  • In vivo efficacy study in a human OC xenograft model shows that NOV202 potently suppresses tumour growth with up to 80%, similar to the“golden standard”, paclitaxel, in this cancer model. The treatment was well tolerated when administered to the animals by oral gavage over a period of 20 days, suggesting low off-target toxicity.
  • tubulin polymerization inhibitor is selected from:
  • combretastatin CA-4P (zybrestat), AVE-8062 (ombrabulin), BNC105P, MPC-6827 (azixa), ZD6126 (ANG453), Oxi-4503, BPI-2358 (plinabulin), MN029 (denibulin), EPC-2407 (crinobulin), ZIO-301 (indibulin), T115, BPR0L075 and ABT-751 or a pharmaceutically acceptable solvate or salt thereof.
  • the tubulin polymerization inhibitor is plinabulin, i.e. a compound of formula II, or a pharmaceutically acceptable solvate or salt thereof.
  • the invention provides olaparib or a pharmaceutically acceptable solvate or salt thereof, plinabulin, or a pharmaceutically acceptable salt, hydrate, solvate or amorphous solid thereof, in combination, for use in treatment of cancer.
  • Embodiments of this aspect are the same as for the embodiments of the first disclosed aspect above.
  • tubulin polymerisation inhibitors Methods and assays for identification and evaluation of potential tubulin polymerisation inhibitors are extensively described in the literature and many assays are commercially available.
  • a fluorescence-based assay can be used wherein polymerization of the tubulin is followed by fluorescence enhancement due to the incorporation of a fluorescent reporter into microtubules as polymerization occurs.
  • the fluorescent assay is based upon the fact that light is scattered by microtubules to an extent that is proportional to the concentration of microtubule polymer.
  • Tubulin polymerisation screening assays are described e.g. in Mol. Cell Biol. 25(2005), 4488-4500, Mol. Cancer Res; 11(8) August 2013, 856-864, and are also commercially available from e.g. Cytoskeleton Inc.
  • said poly (ADP-ribose) polymerase (PARP) inhibitor is selected from olaparib, niraparib, veliparib, talazoparib, rucaparib, iniparib, fluzoparib, AZD2461 , UPF 1069, PJ34, A-966492, AG-14361 , E7449 and NMS-P118.
  • Assays for identification and evaluation of potential PARP inhibitors are extensively described in the literature and many assays are commercially available.
  • colorimetric assays for the screening of PARP inhibitors by measuring the incorporation of a unique biotinylated NAD substrate onto histone proteins can be used.
  • the technology in these assays is ideal for the screening of inhibitors of PARP where the formation of poly(ADP-ribose) chains is inhibited.
  • Such assays are available from i.a. CosmoBio Co and from Trevigen®.
  • a fluorescent screening assay may be used for the identification of PARP-1 inhibitors in an in vitro system. In this technique, the inhibitor is identified by an increase in fluorescent signal when PARP mediated NAD+ depletion is inhibited. Fluorescent screening assays are available from e.g. Trevigen ®
  • said poly (ADP-ribose) polymerase (PARP) inhibitor is olaparib Olaparib is a chemical compound with the following chemical structure:
  • Olaparib has the following IUPAC nomenclature: 4-(3- ⁇ [4 ⁇ (cyclopropylcarbonyl)piperazin-1- y!]carbonyl ⁇ -4-fluorobenzyl)phthalazin-1 (2H)-one.
  • Olaparib is a Poly(ADP-ribose) polymerase (PARP) inhibitor and is known as useful in treatment BRCA deficient ovarian cancer (Meehan and Chen, Gynecologic Oncology Research and Practice (2016) 3:3). Suggested mechanisms of action for olaparib are discussed inter aiia in Yang et a!., Sci Trans! Med. 9 eaal 1645, 2017.
  • said cancer is a primary tumor. In one embodiment, said cancer is a metastasis.
  • said cancer is a solid tumor.
  • said cancer is a BRCA mutated tumor.
  • said cancer is a BRCA mutated breast, ovarian, prostate or pancreas cancer.
  • said cancer is a p53 suppressor gene mutated tumor.
  • said cancer is a p53 mutated breast, ovarian, prostate, lung, brain or pancreas cancer.
  • said cancer is a p53 missense mutated tumor with expression of the full- length mutant p53 protein.
  • said cancer is a p53 missense mutated breast, ovarian, prostate, lung, brain or pancreas cancer with expression of the full-length mutant p53 protein.
  • said cancer is a homologous recombination repair defect tumor with mutations in repair genes other than BRCA1/BRCA2.
  • said cancer is a homologous recombination repair defect breast, ovarian, prostate, lung, brain or pancreas cancer with mutations in repair genes other than
  • said cancer is a homologous recombination repair defect tumor with mutations in repair genes other than BRCA1/BRCA2, such as ATM, ATR, PALB2, RAD51 , CHEK1 and CHEK2, as well as epigenetic loss of BRCA1 function through promoter methylation.
  • said cancer is a homologous recombination repair defect breast, ovarian, prostate, lung, brain or pancreas cancer with mutations in repair genes other than
  • said cancer is selected from the group consisting of breast cancer, lung cancer, ovarian cancer, endometrial cancer, prostate cancer, pharyngeal cancer, esophageal cancer, glioblastoma, adrenal cancer, B-cell malignancies, biliary tract cancer, bladder cancer, bone cancer, brain cancer, cervical cancer, choriocarcinoma, colon cancer, colorectal cancer, connective tissue cancer, cancer of the digestive system, gallbladder cancer, gastric cancer, cancer of the head and neck, hepatocellular carcinoma, intra-epithelial neoplasm, kidney cancer, liver cancer, lymphoma, skin cancer, neuroblastoma, mesothelioma, neuroglioma, oral cavity cancer, pediatric cancer, pancreatic cancer, pancreatic endocrine
  • said cancer is ovarian cancer.
  • Said ovarian cancer may be a BRCA mutated ovarian cancer.
  • Said breast cancer may be selected from estrogen receptor positive or negative, progesterone receptor positive or negative, HER-2 positive or negative, triple-negative breast cancer, or BRCA1 and/or BRCA2 positive or negative breast cancer.
  • Said lung cancer may be selected from non-small cell lung cancer and small cell lung cancer.
  • Said skin cancer may be selected from melanoma and basal cell carcinoma.
  • Said sarcoma may be selected from Ewing's sarcoma, fibrosarcoma, and rhabdomyosarcoma.
  • Said hematological cancer may be selected from leukemia, lymphoma and multiple myeloma.
  • said compound of formula I is A/ 2 -[2-(5-methoxy-1 H-indol-3-yl)ethyl]-/ ⁇ / 4 -(1- methyl-1 H-indol-4-yl)pyrimidine-2, 4-diamine (NOV202); said poly (ADP-ribose) polymerase (PARP) inhibitor is olaparib; and said cancer is ovarian cancer.
  • PARP poly (ADP-ribose) polymerase
  • NOV202 denotes the compound with the IUPAC name N 2 -[2-(5- methoxy-1 H-indol-3-yl)ethyl]-N 4 -(1 -methyl-1 H-indol-4-yl)pyrimidine-2, 4-diamine.
  • the term“olaparib” or“Olaparib” denotes the compound with the IUPAC name 4-(3- ⁇ [4-(cyclopropylcarbonyi)piperazin-1-yl]carbonyl ⁇ -4-fiuorobenzyl)phthalazin-1 (2H)-one.
  • the term“plinabulin” or“Plinabulin” denotes the compound with the IUPAC name (3Z,6Z)-3-Benzylidene-6- ⁇ [5-(2-methyl-2-propanyl)-1/-/-imidazol-4-yl]methylene ⁇ -2,5- piperazinedione.
  • the term“preventing” includes, but is not limited to, inhibiting and/or averting one or more biochemical changes, histologic changes, and/or behavioral symptoms associated with ovarian cancer.
  • treatment or“treating” is an approach for obtaining beneficial and/or desired results, including, but not limited to, clinical results.
  • beneficial and/or desired results include one or more of the following: increasing the quality of life, decreasing the dose of one or more other medications required to treat the disease, delaying the progression of the disease, altering the underlying disease process and/or course, and/or prolonging survival.
  • the terms "effective amount” and “therapeutically effective amount” refer to an amount of a compound or pharmaceutical composition sufficient to produce a desired therapeutic effect including, but not limited to, preventing, and/or delaying onset and/or development of at least one disease.
  • the therapeutically effective amount can vary depending upon the intended application, the subject to be treated (including, e.g., weight and age), the disease and its severity, the route and timing of administration, the desired effect (e.g., lower side effect(s)), the dosing regimen to be used, and the formulation and delivery system (if any).
  • the“therapeutic effective amount” of a drug used in combination with at least one other therapeutic agent may be the same as or different from (either lower or higher) the“therapeutic effective amount” of the drug used individually (i.e. , in a monotherapy).
  • tubulin polymerization inhibitor is administered at a dose ranging from 0.5 to 50 mg/kg per day.
  • the tubulin polymerization inhibitor may be e.g. plinabulin.
  • said compound of formula I is administered at a dose ranging from 0.5 to 50 mg/kg per day.
  • said poly (ADP-ribose) polymerase (PARP) inhibitor is administered at a dose ranging from 0.5 to 100 mg/kg per day.
  • tubulin polymerization inhibitor and/or said poly (ADP-ribose) polymerase (PARP) inhibitor is administered by intravenous infusion.
  • the tubulin polymerization inhibitor may be e.g. plinabulin.
  • said compound of formula I and/or said poly (ADP-ribose) polymerase (PARP) inhibitor is administered by intravenous infusion.
  • tubulin polymerization inhibitor and/or said poly (ADP-ribose) polymerase (PARP) inhibitor is administered orally.
  • the tubulin polymerization inhibitor may be e.g. plinabulin.
  • said compound of formula I and/or said poly (ADP-ribose) polymerase (PARP) inhibitor is administered orally.
  • tubulin polymerization inhibitor and said poly (ADP-ribose) polymerase (PARP) inhibitor is administered once daily, during a 14-day cycle.
  • the tubulin polymerization inhibitor is e.g. plinabulin.
  • said compound of formula I and said poly (ADP-ribose) polymerase (PARP) inhibitor is administered once daily, during a 14-day cycle.
  • a pharmaceutical composition for use in treatment of ovarian cancer comprising a tubulin polymerization inhibitor or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of olaparib or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition for use in treatment of ovarian cancer comprising NOV202 or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of olaparib or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition for use in treatment of ovarian cancer comprising plinabulin or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of olaparib or a pharmaceutically acceptable salt thereof.
  • the invention additionally provides a method of treating, preventing or alleviating cancer, comprising administering to a subject in need thereof (i) a therapeutically effective amount of a tubulin polymerization inhibitor or a pharmaceutically acceptable solvate or salt thereof, and (ii) a therapeutically effective amount of a poly (ADP-ribose) polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate or amorphous solid thereof.
  • the tubulin polymerization inhibitor is a compound of formula I, or a pharmaceutically acceptable solvate or salt thereof,
  • the invention provides a method of treating, preventing or alleviating cancer, comprising administering to a subject in need thereof (i) a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable solvate or salt thereof, and (ii) a therapeutically effective amount of a poly (ADP-ribose) polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate or amorphous solid thereof;
  • PARP poly (ADP-ribose) polymerase
  • R 1 , R 3 , R 8 , R 12 , R 13 , and R 14 represent hydrogen
  • R 2 represents hydrogen or methyl
  • R 4 , R 5 , R 6 , and R 7 are independently selected from hydrogen, halogen, hydroxy, (Ci-C 4 )alkyl, 0(CrC 4 )alkyl, 0(Ci-C 4 )alkyl(C 2 -C 5 )heterocyclyl, and OCF 3 ;
  • R 10 is selected from hydrogen, (CrC4)alkyl and NH2;
  • R 11 is selected from hydrogen, (CrC4)alkyl, (COjNhh, and (C2-C5)heterocyclyl(Ci-C4)alkyl;
  • R 9 is selected from:
  • R 15 is selected from hydrogen and methyl
  • R 16 and R 17 are independently selected from hydrogen, (CrC4)alkyl, (Ci-C4)alkyl-OH, and (CO)OH.
  • tubulin polymerization inhibitor is selected from:
  • combretastatin CA-4P (zybrestat), AVE-8062 (ombrabulin), BNC105P, MPC-6827 (azixa), ZD6126 (ANG453), Oxi-4503, BPI-2358 (plinabulin), MN029 (denibulin), EPC-2407 (crinobulin), ZIO-301 (indibulin), T115, BPR0L075 and ABT-751 or a pharmaceutically acceptable solvate or salt thereof.
  • the tubulin polymerization inhibitor is plinabulin, i.e. a compound of formula II, or a pharmaceutically acceptable solvate or salt thereof.
  • the invention provides a method of treating, preventing or alleviating cancer, comprising administering to a subject in need thereof (i) a therapeutically effective amount of olaparib, or a pharmaceutically acceptable solvate or salt thereof, and (ii) a therapeutically effective amount of plinabulin, or a pharmaceutically acceptable salt, hydrate, solvate or amorphous solid thereof.
  • Embodiments of this aspect are the same as for the embodiments of the aspect disclosed above.
  • Said subject is typically a mammalian subject, including human subjects.
  • the combination therapies disclosed herein may comprise lower doses of one or more of the individual therapies than would be necessary if the individual therapies are given alone (i.e. tubulin polymerization inhibitor, and PARP inhibitor monotherapies). This decreased dose may reduce one or more side-effects associated with the therapies. For example, in some embodiments, the same or greater therapeutic benefit is achieved using a smaller amount (e.g., a lower dose or a less frequent dosing schedule) of said tubulin polymerization inhibitor, and said PARP inhibitor, or both, in the combination therapy than the amount(s) generally used for individual therapy.
  • a smaller amount e.g., a lower dose or a less frequent dosing schedule
  • the use of a small amount of said tubulin polymerization inhibitor, said PARP inhibitor, or both results in a reduction in the number, severity, frequency and/or duration of one or more side- effects associated with the compounds.
  • the combination therapy may comprise, compared to the doses generally used for individual therapies: (i) lower dose of said tubulin polymerization inhibitor and lower dose of said PARP inhibitor; (ii) lower dose of said tubulin polymerization inhibitor and the same dose of said PARP inhibitor; (iii) lower dose of said PARP inhibitor and the same dose of said tubulin polymerization inhibitor.
  • the tubulin polymerization inhibitor may be e.g. plinabulin.
  • the combination therapies disclosed herein may comprise lower doses of one or more of the individual therapies than would be necessary if the individual therapies are given alone (i.e. compound of formula I, and PARP inhibitor monotherapies). This decreased dose may reduce one or more side-effects associated with the therapies. For example, in some embodiments, the same or greater therapeutic benefit is achieved using a smaller amount (e.g., a lower dose or a less frequent dosing schedule) of said compound of formula I, and said PARP inhibitor, or both, in the combination therapy than the amount(s) generally used for individual therapy.
  • a smaller amount e.g., a lower dose or a less frequent dosing schedule
  • the use of a small amount of said compound of formula I, said PARP inhibitor, or both results in a reduction in the number, severity, frequency and/or duration of one or more side-effects associated with the compounds.
  • the combination therapy may comprise, compared to the doses generally used for individual therapies: (i) lower dose of said compound of formula I and lower dose of said PARP inhibitor; (ii) lower dose of said compound of formula I and the same dose of said PARP inhibitor; (iii) lower dose of said PARP inhibitor and the same dose of said compound of formula I.
  • the combination therapies disclosed herein may comprise higher doses of the individual therapies than would be necessary if the individual therapies were given alone (i.e., said tubulin polymerization inhibitor and said PARP inhibitor monotherapies).
  • the dose of one of the drugs is lower than its dose generally used for individual therapy, while the other drug is given at an equal or higher dose than its dose generally used for individual therapy.
  • the combination therapy may comprise (i) higher dose of said PARP inhibitor and lower dose of said tubulin polymerization inhibitor; or (ii) higher dose of said tubulin polymerization inhibitor and lower dose of said PARP inhibitor.
  • the combination therapy may comprise, compared to the dosages generally used for individual therapies, (i) higher dose of said PARP inhibitor and higher dose of said tubulin polymerization inhibitor; (ii) higher dose of said tubulin
  • the tubulin polymerization inhibitor may be e.g. plinabulin.
  • the combination therapies disclosed herein may comprise higher doses of the individual therapies than would be necessary if the individual therapies were given alone (i.e., said compound of formula I and said PARP inhibitor monotherapies).
  • the dose of one of the drugs is lower than its dose generally used for individual therapy, while the other drug is given at an equal or higher dose than its dose generally used for individual therapy.
  • the combination therapy may comprise (i) higher dose of said PARP inhibitor and lower dose of said compound of formula I; or (ii) higher dose of said compound of formula I and lower dose of said PARP inhibitor.
  • the combination therapy may comprise, compared to the dosages generally used for individual therapies, (i) higher dose of said PARP inhibitor and higher dose of said compound of formula I; (ii) higher dose of said compound of formula I and the same dose of said PARP inhibitor; or (iii) higher dose of said PARP inhibitor and the same dose of said compound of formula I.
  • the combination therapy disclosed herein reduces the severity of one or more symptoms associated with ovarian cancer by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% or more, as compared to the corresponding symptom in the same subject prior to treatment or as compared to the corresponding symptom in other subjects not receiving the combination therapy.
  • the administration of the tubulin polymerization inhibitor and said PARP inhibitor results in a reduction of the decline in the measure of ovarian cancer, such as at least 10%, 20%, 30%, 40%, 50%, 60%, 70%,
  • the administration of the combination of said compound of formula I and said PARP inhibitor results in a reduction of the decline in the measure of ovarian cancer, such as at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% or more, as compared to a control.
  • combinations of said tubulin polymerization inhibitor and said PARP inhibitor may be administered to a subject in a single dosage form and/or by separate administration of each active agent.
  • the tubulin polymerization inhibitor may be e.g. plinabulin.
  • combinations of said compound of formula I and said PARP inhibitor may be administered to a subject in a single dosage form and/or by separate administration of each active agent.
  • tubulin polymerization inhibitor and said PARP inhibitor may be formulated into a tablet, pill, capsule, or solution.
  • the formulation of tubulin polymerization inhibitor and said PARP inhibitor may be selected appropriately.
  • said tubulin polymerization inhibitor, said PARP inhibitor or both are formulated into a solution for parenteral administration.
  • said tubulin polymerization inhibitor and said PARP inhibitor may be formulated in segregated regions or distinct caplets of housed within a capsule.
  • said tubulin polymerization inhibitor and said PARP inhibitor may be formulated in isolated layers in a tablet.
  • the tubulin polymerization inhibitor may be e.g. plinabulin.
  • said compound of formula I and said PARP inhibitor may be formulated into a tablet, pill, capsule, or solution.
  • the formulation of said compound of formula I and said PARP inhibitor may be selected appropriately.
  • said compound of formula I, said PARP inhibitor or both are formulated into a solution for parenteral administration.
  • said compound of formula I and said PARP inhibitor may be formulated in segregated regions or distinct caplets of housed within a capsule.
  • said compound of formula I and said PARP inhibitor may be formulated in isolated layers in a tablet.
  • the pharmaceutical composition for treating, preventing, and/or delaying onset and/or development of ovarian cancer comprises a therapeutically effective amount of said tubulin polymerization inhibitor, a therapeutically effective amount of said PARP inhibitor, and at least one pharmaceutically acceptable carrier.
  • the tubulin polymerization inhibitor may be e.g. plinabulin.
  • the pharmaceutical composition for treating, preventing, and/or delaying onset and/or development of ovarian cancer comprises a therapeutically effective amount of said compound of formula I, a therapeutically effective amount of said PARP inhibitor, and at least one pharmaceutically acceptable carrier.
  • tubulin polymerization inhibitor and said PARP inhibitor may be administered as separate compositions and optionally as different forms, e.g., as separate tablets or solutions.
  • said PARP inhibitor is administered as once daily oral tablets and said tubulin polymerization inhibitor is administered as once daily oral tablets.
  • both said tubulin polymerization inhibitor and said PARP inhibitor are administered, separately, as oral tablets.
  • both said tubulin polymerization inhibitor and said PARP inhibitor are administered separately, as injections.
  • the tubulin polymerization inhibitor may be e.g. plinabulin.
  • said compound of formula I and said PARP inhibitor may be administered as separate compositions and optionally as different forms, e.g., as separate tablets or solutions.
  • said PARP inhibitor is administered as once daily oral tablets and said compound of formula I is administered as once daily oral tablets.
  • both said compound of formula I and said PARP inhibitor are administered, separately, as oral tablets.
  • both said compound of formula I and said PARP inhibitor are administered separately, as injections.
  • tubulin polymerization inhibitor and said PARP inhibitor are administered as separate compositions:
  • compositions for use in combination with said PARP inhibitor for treating, preventing, and/or delaying the onset and/or development of cancer comprising a therapeutically effective amount of said tubulin polymerization inhibitor and at least one pharmaceutically acceptable carrier is administered separately;
  • polymerization inhibitor for treating, preventing, and/or delaying the onset and/or development of cancer comprising a therapeutically effective amount of said PARP inhibitor and at least one pharmaceutically acceptable carrier is administered separately.
  • compositions for use in combination with said PARP inhibitor for treating, preventing, and/or delaying the onset and/or development of cancer comprising a therapeutically effective amount of said compound of formula I and at least one pharmaceutically acceptable carrier is administered separately;
  • compositions for use in combination with said compound of formula I for treating, preventing, and/or delaying the onset and/or development of cancer comprising a therapeutically effective amount of said PARP inhibitor and at least one pharmaceutically acceptable carrier is administered separately.
  • kits for use in treating cancer or decreasing tumor size comprising (i) a tubulin polymerization inhibitor or a pharmaceutically acceptable solvate or salt thereof; and (ii) a poly (ADP-ribose) polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate or amorphous solid thereof.
  • the tubulin polymerization inhibitor may be e.g. plinabulin.
  • kits for use in treating cancer or decreasing tumor size comprising (i) a compound of formula I or a pharmaceutically acceptable solvate or salt thereof; and (ii) a poly (ADP-ribose) polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate or amorphous solid thereof.
  • PARP poly (ADP-ribose) polymerase
  • said compound of formula I is A/ 2 -[2-(5-methoxy-1 H-indol-3-yl)ethyl]-/ ⁇ / 4 -(1- methyl-1 H-indol-4-yl)pyrimidine-2, 4-diamine (NOV202); said poly (ADP-ribose) polymerase (PARP) inhibitor is olaparib; and said cancer is ovarian cancer.
  • PARP poly (ADP-ribose) polymerase
  • tubulin polymerization inhibitor is plinabulin; said poly (ADP- ribose) polymerase (PARP) inhibitor is olaparib; and said cancer is ovarian cancer.
  • PARP poly (ADP- ribose) polymerase
  • tubulin polymerization inhibitor and said PARP inhibitor may be administered simultaneously. In some embodiments, said tubulin polymerization inhibitor and said PARP inhibitor may be administered sequentially. In some embodiments, said tubulin polymerization inhibitor and said PARP inhibitor may be administered intermittently. The length of time between administrations of said tubulin polymerization inhibitor and said PARP inhibitor may be adjusted to achieve the desired therapeutic effect. In some embodiments, said tubulin polymerization inhibitor and said PARP inhibitor may be administered only a few minutes apart. In some embodiments, said tubulin polymerization inhibitor and said PARP inhibitor may be administered several hours (e.g., about 2, 4, 6, 10, 12, 24, or 36 h) apart. In some
  • tubulin polymerization inhibitor may be advantageous to administer more than one dosage of one of said tubulin polymerization inhibitor and said PARP inhibitor between administrations of the remaining therapeutic agent.
  • one therapeutic agent may be administered at 1 hour and then again at 11 hours following administration of the other therapeutic agent.
  • the therapeutic effects of each said tubulin polymerization inhibitor and said PARP inhibitor should overlap for at least a portion of the duration, so that the overall therapeutic effect of the combination therapy may be attributable in part to the combined or synergistic effects of the combination therapy.
  • the tubulin polymerization inhibitor may be e.g. plinabulin.
  • said compound of formula I and said PARP inhibitor may be any organic compound of formula I and said PARP inhibitor.
  • said compound of formula I and said PARP inhibitor may be administered simultaneously.
  • said compound of formula I and said PARP inhibitor may be administered sequentially.
  • said compound of formula I and said PARP inhibitor may be administered intermittently. The length of time between administrations of said compound of formula I and said PARP inhibitor may be adjusted to achieve the desired therapeutic effect.
  • said compound of formula I and said PARP inhibitor may be administered only a few minutes apart.
  • said compound of formula I and said PARP inhibitor may be administered several hours (e.g., about 2, 4, 6, 10, 12, 24, or 36 h) apart. In some embodiments, it may be
  • one therapeutic agent may be administered at 1 hour and then again at 11 hours following administration of the other therapeutic agent.
  • the therapeutic effects of each said compound of formula I and said PARP inhibitor should overlap for at least a portion of the duration, so that the overall therapeutic effect of the combination therapy may be attributable in part to the combined or synergistic effects of the combination therapy.
  • the dosage of said tubulin polymerization inhibitor and said PARP inhibitor may be dependent upon a number of factors including pharmacodynamic characteristics of each agent, mode route of administration, the health of the patient being treated, the extent of treatment desired, the nature and kind of concurrent therapy, if any, the frequency of treatment, and the nature of the effect desired.
  • said tubulin polymerization inhibitor may be administered at a dose ranging from 0.001 mg/kg body weight per day to 100 mg/kg body weight per day.
  • said PARP inhibitor may be administered at a dose ranging from 5 mg/day to 1200 mg/day, 5 mg/day to 500 mg/day, 10 mg/day to 75 mg/day, 5 mg/day to 50 mg/day, 15 mg/day to 50 mg/day, or 200 mg/day to 400 mg/day. In some embodiments, said PARP inhibitor may be administered at a dose ranging from about 5 mg/ day to about 100 mg/day, about 10 mg/day to about 75 mg/day, about 5 mg/day to about 50 mg/day, about 15 mg/day to about 50 mg/day, or about 200 mg/day to about 400 mg/day. In some embodiments, said PARP inhibitor may be administered at a dose of 5 mg/day, 10 mg/day, 15 mg/day, 20 mg/day, 25 mg/day, 30 mg/day, 50 mg/day, 75 mg/day, 100 mg/day,
  • the tubulin polymerization inhibitor may be e.g. plinabulin.
  • the dosage of said compound of formula I and said PARP inhibitor may be dependent upon a number of factors including pharmacodynamic characteristics of each agent, mode route of administration, the health of the patient being treated, the extent of treatment desired, the nature and kind of concurrent therapy, if any, the frequency of treatment, and the nature of the effect desired.
  • said compound of formula I may be administered at a dose ranging from 0.001 mg/kg body weight per day to 100 mg/kg body weight per day.
  • said PARP inhibitor may be administered at a dose ranging from 5 mg/ day to 500 mg/day, 10 mg/day to 75 mg/day, 5 mg/day to 50 mg/day, 15 mg/day to 50 mg/day, or 200 mg/day to 400 mg/day.
  • said PARP inhibitor may be administered at a dose ranging from about 5 mg/ day to about 100 mg/day, about 10 mg/day to about 75 mg/day, about 5 mg/day to about 50 mg/day, about 15 mg/day to about 50 mg/day, or about 200 mg/day to about 400 mg/day. In some embodiments, said PARP inhibitor may be administered at a dose of 5 mg/day, 10 mg/day, 15 mg/day, 20 mg/day, 25 mg/day, 30 mg/day, 50 mg/day, 75 mg/day, 100 mg/day, 200 mg/day, or 400 mg/day dosage.
  • said PARP inhibitor may be administered at a dose ranging from 5 mg/ day to 1200 mg/day In some embodiments, said PARP inhibitor may be administered at a dose of 1200 mg/day.
  • said tubulin polymerization inhibitor may be administered at a dose ranging from 1 mg/kg to 50 mg/kg, 2.5 mg/kg to 30 mg/kg, 2.5 mg/kg to 5 mg/kg, or 5 mg/kg to 10 mg/kg. In some embodiments, said tubulin polymerization inhibitor is administered at a dose of 10 mg/kg every 2 weeks. In some embodiments, said compound of formula I is administered at a dose of 5 mg/kg every 2 weeks. In some embodiments, said tubulin polymerization inhibitor is administered at a dose of 2.5 mg/kg every 2 weeks. In some embodiments, said tubulin polymerization inhibitor is administered at a dose of 5 mg/kg every month. In some embodiments, said tubulin polymerization inhibitor is administered at a dose of 10 mg/kg every month. The tubulin polymerization inhibitor may be e.g. plinabulin.
  • said compound of formula I may be administered at a dose ranging from 1 mg/kg to 50 mg/kg, 2.5 mg/kg to 30 mg/kg, 2.5 mg/kg to 5 mg/kg, or 5 mg/kg to 10 mg/kg. In some embodiments, said compound of formula I is administered at a dose of 10 mg/kg every 2 weeks. In some embodiments, said compound of formula I is administered at a dose of 5 mg/kg every 2 weeks. In some embodiments, said compound of formula I is administered at a dose of 2.5 mg/kg every 2 weeks. In some embodiments, said compound of formula I is administered at a dose of 5 mg/kg every month. In some embodiments, said compound of formula I is administered at a dose of 10 mg/kg every month.
  • the tubulin polymerization inhibitor is a compound of formula I.
  • the compound of formula I is L/ 2 - ⁇ - ⁇ - methoxy-1 H-indol-3-yl)ethyl]-/V 4 -(1 -methyl-1 H-indol-4-yl)pyrimidine-2, 4-diamine (NOV202).
  • the tubulin polymerization inhibitor is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • tubulin polymerization inhibitor is plinabulin.
  • the tubulin polymerization inhibitor is plinabulin.
  • Figure 1 sets out results of study of an in vivo anti-tumor efficacy of NOV202 alone and in combination with olaparib in a patient-derived xenograft of ovarian cancer. Details are provided in Example 1.
  • Figure 2 sets out the mean body weight changes of an in vivo anti-tumor efficacy of NOV202 alone and in combination with olaparib in a patient-derived xenograft of ovarian cancer. Details are provided in Example 1.
  • Figure 3 sets out results of study of an in vivo anti-tumor efficacy of NOV202, olaparib and plinabulin alone, and combination of NOV202 and olaparib, and combination of plinabulin and olaparib, in a patient-derived xenograft of ovarian cancer. Details are provided in Example 2.
  • A represents vehicle
  • B represents NOV202
  • C represents olaparib
  • D represents plinabulin
  • E represents combination of NOV202 and olaparib
  • F represents combination of plinabulin and olaparib. Start of treatments were at day 6 and end of treatment were at day 19 (NOV202 and olaparib) and at day 20 (plinabulin).
  • Figure 4 sets out the mean body weight changes of an in vivo anti-tumor efficacy of NOV202, olaparib and plinabulin alone, and combination of NOV202 and olaparib, and combination of plinabulin and olaparib, in a patient-derived xenograft of ovarian cancer Details are provided in Example 2.
  • A represents vehicle
  • B represents NOV202
  • C represents olaparib
  • D represents plinabulin
  • E represents combination of NOV202 and olaparib
  • F represents combination of plinabulin and olaparib.
  • NMRI nu/nu female mice (8 weeks old) mice (8 weeks old) were used as follows: 4 animals in the vehicle group, 4 animals in NOV202 group, Olaparib group and in the combination group of NOV202 and olaparib, respectively.
  • NOV202 was synthesized as described in WO 2012/127032.
  • Olaparib was purchased from LC Laboratories. The patient-derived xenograft Ov10584 was used at passage number 7. All mice received tissue fragments of 2x2 mm subcutaneously at day 0, and tumors were allowed to reach palpable sizes of 118 mm 3 (mean) (the study day 8) prior to start the treatments.
  • NOV202 group was administered PO at a dose 30 mg/kg and olaparib group was administered PO at a dose 100 g/kg. The combination of NOV202 and olaparib group had the same dosage and schedule as in monotherapy. NOV202 was given in the morning (5 ml/kg) and olaparib in the afternoon (10 ml/kg). All three groups were
  • NOV202 inhibited the growth of Ov10584 significantly, resulting in a T/C (tumor/control) value of 37 % (stable disease).
  • the combination of NOV202 with olaparib had a distinct synergistic effect.
  • mice Daily treatment with 30 mg/kg NOV202 for 14 days was well tolerated. One day after treatment stop, mice showed 6 % body weight loss but they recovered soon. The combination of NOV202 and olaparib was also well tolerated. Results are set out in Figure 1. The mean body weight changes of the animals are set out in Figure 2.
  • NMRI nu/nu female mice (8 weeks old) mice (8 weeks old) were used as follows: 4 animals in the vehicle group, 4 animals in NOV202 group, olaparib group, plinabulin group, in the combination group of NOV202 and Olaparib, and in the combination group of plinabulin and olaparib, respectively.
  • NOV202 was synthesized as described in WO 2012/127032.
  • Olaparib was purchased from LC Laboratories, and plinabulin was purchased from Sellechem.
  • the patient-derived xenograft Ov10584 was used at passage number 4. All mice received tissue fragments of 2x2 mm subcutaneously into the left flank at day 0, and tumors were allowed to reach palpable sizes of 108 mm 3 (mean) (the study day 6) prior to start the treatments.
  • NOV202 group was
  • NOV202 and olaparib group had the same dosage and schedule as in monotherapy, NOV202 was given in the morning (5 ml/kg) and olaparib in the afternoon (10 ml/kg).
  • the combination of plinabulin and olaparib group had also the same dosage and schedule as in monotherapy.
  • NOV202 and olaparib was administered 14 days once a day (days 6 - 19), and plinabulin was administered days 1 , 4, 8, 11 , 15 once a day.
  • the tumor volumes and body weights of animals were measured at regular intervals (day 6, 7, 9, 12, 14, 16, 19, 23, 26 and 29), all groups.
  • NOV202 inhibited the growth of Ov10584 significantly, resulting in a T/C (tumor/control) value of 32 % (stable disease).
  • the combination of NOV202 with olaparib had a distinct synergistic effect.
  • the T/C value was improved to 6 % in the combination group, compared to 32 % for NOV202, 45 % for olaparib and 58 % for plinabulin after monotherapy.
  • the combination of plinabulin with olaparib had also a synergistic effect.
  • T/C value was improved to 14 % in the combination group.
  • Results are set out in Figure 3.
  • the mean body weight changes of the animals are set out in Figure 4.
  • A represents vehicle
  • B represents NOV202
  • C represents olaparib
  • D represents plinabulin
  • E represents combination of NOV202 and olaparib
  • F represents combination of plinabulin and olaparib.
  • a method of treating, preventing or alleviating cancer comprising administering to a
  • a therapeutically effective amount of a tubulin polymerization inhibitor or a pharmaceutically acceptable salt, hydrate, solvate or amorphous solid thereof and (ii) a therapeutically effective amount of a poly (ADP-ribose) polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate or amorphous solid thereof.
  • PARP poly (ADP-ribose) polymerase
  • tubulin polymerization inhibitor is a compound of
  • R 1 , R 3 , R 8 , R 12 , R 13 , and R 14 represent hydrogen
  • R 2 represents hydrogen or methyl
  • R 4 , R 5 , R 6 , and R 7 are independently selected from hydrogen, halogen, hydroxy, (Cr C 4 )alkyl, 0(CrC 4 )alkyl, 0(Ci-C 4 )alkyl(C 2 -C 5 )heterocyclyl, and OCF 3 ;
  • R 10 is selected from hydrogen, (CrC4)alkyl and Nhh;
  • R 11 is selected from hydrogen, (CrC4)alkyl, (CO)NH2, and (C2-C5)heterocyclyl(Ci-C4)alkyl; R 9 is selected from
  • R 15 is selected from hydrogen and methyl
  • R 16 and R 17 are independently selected from hydrogen, (CrC4)alkyl, (Ci-C4)alkyl-OH, and (CO)OH.
  • A/ 2 [2-(5-methoxy-1 /-/-indol-3-yl)ethyl]-5-methyl-A/ 4 -(2-methyl-1 /-/-indol-5-yl)pyrimidine-2,4- diamine;
  • A/ 2 [2-(5-ethoxy-1 /-/-indol-3-yl)ethyl]-6-methyl-/ ⁇ / 4 -(2-methyl-1 /-/-indol-5-yl)pyrimidine-2,4- diamine;
  • tubulin polymerization inhibitor is a I compound of formula I which is A/ 2 -[2-(5-methoxy-1 H-indol-3-yl)ethyl]-/ ⁇ / 4 -(1 -methyl-1 H-indol-4- yl)pyrimidine-2, 4-diamine (NOV202).
  • tubulin polymerization inhibitor is selected from
  • combretastatin CA-4P (zybrestat), AVE-8062 (ombrabulin), BNC105P, MPC-6827 (azixa), ZD6126 (ANG453), Oxi-4503, BPI-2358 (plinabulin), MN029 (denibulin), EPC-2407 (crinobulin), ZIO-301 (indibulin), T115, BPR0L075 and ABT-751.
  • PARP polymerase
  • PARP polymerase
  • BRCA1/BRCA2 such as ATM, ATR, PALB2, RAD51 , CHEK1 and CHEK2, as well as epigenetic loss of BRCA1 function through promoter methylation.
  • any one of items 1 to 10 wherein said cancer is selected from the group consisting of breast cancer, lung cancer, ovarian cancer, endometrial cancer, prostate cancer, pharyngeal cancer, esophageal cancer, glioblastoma, adrenal cancer, B- cell malignancies, biliary tract cancer, bladder cancer, bone cancer, brain cancer, cervical cancer, choriocarcinoma, colon cancer, colorectal cancer, connective tissue cancer, cancer of the digestive system, gallbladder cancer, gastric cancer, cancer of the head and neck, hepatocellular carcinoma, intra-epithelial neoplasm, kidney cancer, liver cancer, lymphoma, skin cancer, neuroblastoma, mesothelioma, neuroglioma, oral cavity cancer, pediatric cancer, pancreatic cancer, pancreatic endocrine tumors, pituitary adenoma, thymoma, renal cell carcinoma, cancer of the respiratory system, salivary gland cancer, sarcom
  • breast cancer is selected from estrogen receptor positive or negative, progesterone receptor positive or negative, HER-2 positive or negative, triple-negative breast cancer, or BRCA1 and/or BRCA2 positive or negative breast cancer.
  • leukemia leukemia, lymphoma and multiple myeloma.
  • PARP polymerase
  • tubulin polymerization inhibitor and/or said poly (ADP-ribose) polymerase (PARP) inhibitor is administered by intravenous infusion.
  • tubulin polymerization inhibitor and/or said poly (ADP-ribose) polymerase (PARP) inhibitor is administered orally.
  • tubulin polymerization inhibitor and said poly (ADP-ribose) polymerase (PARP) inhibitor is administered once daily, during a 14-day cycle.
  • tubulin polymerization inhibitor is administered at a dose ranging from 0.5 to 50 mg/kg per day.
  • polymerization inhibitor is a compound of formula I which is / ⁇ - ⁇ -(S-methoxy-l H-indol-3- yl)ethyl]-/ ⁇ / 4 -(1 -methyl-1 H-indol-4-yl)pyrimidine-2, 4-diamine (NOV202); said poly (ADP- ribose) polymerase (PARP) inhibitor is olaparib; and said cancer is ovarian cancer.
  • PARP poly (ADP- ribose) polymerase
  • tubulin polymerization inhibitor is plinabulin or a
  • the PARP inhibitor is olaparib or a pharmaceutically acceptable solvate or salt thereof.
  • PARP poly (ADP-ribose) polymerase
  • R 1 , R 3 , R 8 , R 12 , R 13 , and R 14 represent hydrogen
  • R 2 represents hydrogen or methyl
  • R 4 , R 5 , R 6 , and R 7 are independently selected from hydrogen, halogen, hydroxy, (Cr C 4 )alkyl, 0(CrC 4 )alkyl, 0(Ci-C 4 )alkyl(C 2 -C 5 )heterocyclyl, and OCF 3 ;
  • R 10 is selected from hydrogen, (CrC4)alkyl and Nhh;
  • R 11 is selected from hydrogen, (CrC4)alkyl, (CO)NH2, and (C2-C5)heterocyclyl(Ci-C4)alkyl; R 9 is selected from
  • R 15 is selected from hydrogen and methyl
  • R 16 and R 17 are independently selected from hydrogen, (CrC4)alkyl, (Ci-C4)alkyl-OH, and (CO)OH.
  • A/ 2 [2-(5-methoxy-1 /-/-indol-3-yl)ethyl]-5-methyl-A/ 4 -(2-methyl-1 /-/-indol-5-yl)pyrimidine-2,4- diamine;
  • A/ 2 [2-(5-ethoxy-1 /-/-indol-3-yl)ethyl]-6-methyl-/ ⁇ / 4 -(2-methyl-1 /-/-indol-5-yl)pyrimidine-2,4- diamine;
  • PARP poly (ADP- ribose) polymerase
  • said poly (ADP- ribose) polymerase (PARP) inhibitor is selected from olaparib, niraparib, veliparib, talazoparib, rucaparib, iniparib, fluzoparib, AZD2461 , UPF 1069, PJ34, A-966492, AG- 14361 , E7449 and NMS-P118. 44.
  • said poly (ADP- ribose) polymerase (PARP) inhibitor is olaparib.
  • glioblastoma adrenal cancer
  • B-cell malignancies biliary tract cancer
  • bladder cancer bone cancer
  • brain cancer cervical cancer
  • choriocarcinoma colon cancer
  • colorectal cancer connective tissue cancer
  • cancer of the digestive system gallbladder cancer
  • gastric cancer cancer of the head and neck
  • hepatocellular carcinoma intra-epithelial neoplasm
  • kidney cancer liver cancer
  • lymphoma skin cancer
  • neuroblastoma mesothelioma
  • neuroglioma oral cavity cancer
  • pediatric cancer pancreatic cancer, pancreatic endocrine tumors, pituitary adenoma, thymoma, renal cell carcinoma, cancer of the respiratory system, salivary gland cancer, sarcoma, small bowel cancer, testicular cancer, thyroid cancer, ureteral cancer, cancer of the urinary system, and hematological cancer.
  • breast cancer is selected from estrogen receptor positive or negative, progesterone receptor positive or negative, HER-2 positive or negative, triple-negative breast cancer, or BRCA1 and/or BRCA2 positive or negative breast cancer.
  • sarcoma is selected from Ewing's sarcoma, fibrosarcoma, and rhabdomyosarcoma.
  • leukemia selected from leukemia, lymphoma and multiple myeloma.
  • a pharmaceutical composition for use in treatment of ovarian cancer comprising NOV202 and/or a pharmaceutically acceptable salt thereof, and olaparib and/or a pharmaceutically acceptable salt thereof.
  • kits for use in treating cancer or decreasing tumor size comprising (i) a
  • kit for use wherein said compound of formula I is L/ 2 - ⁇ - ⁇ - methoxy-1 H-indol-3-yl)ethyl]-/ ⁇ / 4 -(1 -methyl-1 H-indol-4-yl)pyrimidine-2, 4-diamine (NOV202); said poly (ADP-ribose) polymerase (PARP) inhibitor is olaparib; and said cancer is ovarian cancer.
  • PARP poly (ADP-ribose) polymerase
  • Olaparib or a pharmaceutically acceptable solvate or salt thereof, and plinabulin, or a pharmaceutically acceptable salt, hydrate, solvate or amorphous solid thereof, in combination, for use in treatment of cancer.
  • PARP poly (ADP-ribose) polymerase
  • combretastatin CA-4P (zybrestat), AVE-8062 (ombrabulin), BNC105P, MPC-6827 (azixa), ZD6126 (ANG453), Oxi-4503, BPI-2358 (plinabulin), MN029 (denibulin), EPC-2407 (crinobulin), ZIO-301 (indibulin), T115 or BPR0L075, ABT-751.
  • PARP poly (ADP- ribose) polymerase
  • said poly (ADP- ribose) polymerase (PARP) inhibitor is selected from olaparib, niraparib, veliparib, talazoparib, rucaparib, iniparib, fluzoparib, AZD2461 , UPF 1069, PJ34, A-966492, AG- 14361 , E7449 and NMS-P118.
  • PARP poly (ADP- ribose) polymerase

Abstract

L'invention concerne des méthodes et des polythérapies permettant de traiter, de prévenir et/ou de retarder l'apparition et/ou le développement d'un cancer en faisant appel à un inhibiteur de polymérisation de la tubuline tel qu'un composé de formule I, ou un sel pharmaceutiquement acceptable de celui-ci, et à un inhibiteur de la poly(ADP-ribose) polymérase (PARP), ou un sel pharmaceutiquement acceptable de celui-ci.
PCT/SE2019/050312 2018-04-05 2019-04-04 Nouvelles associations d'un inhibiteur de polymérisation de la tubuline et d'un inhibiteur de la poly(adp-ribose) polymérase (parp) destinées à être utilisées dans le traitement du cancer WO2019194738A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP19781419.7A EP3773592A4 (fr) 2018-04-05 2019-04-04 Nouvelles associations d'un inhibiteur de polymérisation de la tubuline et d'un inhibiteur de la poly(adp-ribose) polymérase (parp) destinées à être utilisées dans le traitement du cancer
US16/981,232 US11590130B2 (en) 2018-04-05 2019-04-04 Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer
JP2020551269A JP7372253B2 (ja) 2018-04-05 2019-04-04 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ
CN201980024687.3A CN111936143A (zh) 2018-04-05 2019-04-04 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品
CA3095709A CA3095709A1 (fr) 2018-04-05 2019-04-04 Nouvelles associations d'un inhibiteur de polymerisation de la tubuline et d'un inhibiteur de la poly(adp-ribose) polymerase (parp) destinees a etre utilisees dans le traitement du cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1850380-5 2018-04-05
SE1850380 2018-04-05

Publications (1)

Publication Number Publication Date
WO2019194738A1 true WO2019194738A1 (fr) 2019-10-10

Family

ID=68101552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2019/050312 WO2019194738A1 (fr) 2018-04-05 2019-04-04 Nouvelles associations d'un inhibiteur de polymérisation de la tubuline et d'un inhibiteur de la poly(adp-ribose) polymérase (parp) destinées à être utilisées dans le traitement du cancer

Country Status (6)

Country Link
US (1) US11590130B2 (fr)
EP (1) EP3773592A4 (fr)
JP (1) JP7372253B2 (fr)
CN (1) CN111936143A (fr)
CA (1) CA3095709A1 (fr)
WO (1) WO2019194738A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021225908A1 (fr) * 2020-05-04 2021-11-11 Beyondspring Pharmaceuticals, Inc. Trithérapie pour améliorer la destruction de cellules cancéreuses dans des cancers à faible immunogénicité
US11857522B2 (en) 2016-02-08 2024-01-02 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
US11918574B2 (en) 2015-03-06 2024-03-05 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009118384A1 (fr) * 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Dérivés de quinazolinone comme inhibiteurs de la polymérisation de la tubuline
WO2017013593A1 (fr) * 2015-07-22 2017-01-26 Lupin Limited Dérivés d'isoquinolinone utilisés en tant qu'inhibiteurs de parp
WO2017083979A1 (fr) * 2015-11-20 2017-05-26 Lee Hoyun Composés de quinolone chalcone et leurs utilisations
US20170209594A1 (en) * 2015-06-25 2017-07-27 Immunomedics, Inc. Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or parp inhibitors
WO2017223516A1 (fr) * 2016-06-24 2017-12-28 The Regents Of The University Of California Dérivés de phtalazine utiles en tant qu'inhibiteurs de parp1, parp2 et/ou de tubuline dans le traitement du cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070265324A1 (en) 2006-01-17 2007-11-15 Wolfgang Wernet Combination Therapy with Parp Inhibitors
BRPI0811059A2 (pt) 2007-05-25 2017-05-09 Astrazeneca Ab combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
CA2705417A1 (fr) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Traitement du cancer de l'uterus et du cancer de l'ovaire avec un inhibiteur parp utilise seul ou en combinaison avec des antitumoraux
CN101888777A (zh) 2007-12-07 2010-11-17 彼帕科学公司 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症
WO2009118382A1 (fr) 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Tétrahydrophénanthridinones et tétrahydrocyclopentaquinolinones comme inhibiteurs de la polymérisation de la tubuline et de parp
AR075239A1 (es) 2009-02-04 2011-03-16 Bipar Sciences Inc Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso
US8541417B2 (en) 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
CA2799653A1 (fr) * 2010-06-04 2011-12-08 Bertrand Leblond Isoquinoleines substituees et leur utilisation en tant qu'inhibiteurs de polymerisation des tubulines
WO2012127032A1 (fr) 2011-03-24 2012-09-27 Chemilia Ab Nouveaux dérivés de pyrimidine
EP3925962A1 (fr) 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Inhibiteurs tricycliques de poly(adp-ribose)polymérase
US9132120B1 (en) 2012-04-02 2015-09-15 Stc.Unm Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers
PL2984184T3 (pl) 2013-04-09 2021-06-14 The Board Of Trustees Of The University Of Illinois Stosowanie DNQ lub DNQ-87 w połączeniu z inhibitorem PARP1 do leczenia nowotworu

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009118384A1 (fr) * 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Dérivés de quinazolinone comme inhibiteurs de la polymérisation de la tubuline
US20170209594A1 (en) * 2015-06-25 2017-07-27 Immunomedics, Inc. Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or parp inhibitors
WO2017013593A1 (fr) * 2015-07-22 2017-01-26 Lupin Limited Dérivés d'isoquinolinone utilisés en tant qu'inhibiteurs de parp
WO2017083979A1 (fr) * 2015-11-20 2017-05-26 Lee Hoyun Composés de quinolone chalcone et leurs utilisations
WO2017223516A1 (fr) * 2016-06-24 2017-12-28 The Regents Of The University Of California Dérivés de phtalazine utiles en tant qu'inhibiteurs de parp1, parp2 et/ou de tubuline dans le traitement du cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU, X. ET AL.: "Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations", CANCER CHEMOTH. PHARM., vol. 81, 2018, pages 255 - 267, XP036390677, DOI: 10.1007/s00280-017-3483-6 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11918574B2 (en) 2015-03-06 2024-03-05 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
US11857522B2 (en) 2016-02-08 2024-01-02 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
WO2021225908A1 (fr) * 2020-05-04 2021-11-11 Beyondspring Pharmaceuticals, Inc. Trithérapie pour améliorer la destruction de cellules cancéreuses dans des cancers à faible immunogénicité

Also Published As

Publication number Publication date
EP3773592A4 (fr) 2022-02-23
CA3095709A1 (fr) 2019-10-10
US20210052583A1 (en) 2021-02-25
EP3773592A1 (fr) 2021-02-17
US11590130B2 (en) 2023-02-28
JP7372253B2 (ja) 2023-10-31
JP2021519262A (ja) 2021-08-10
CN111936143A (zh) 2020-11-13

Similar Documents

Publication Publication Date Title
JP6783224B2 (ja) 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
Neckers et al. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics–an update
Chan et al. Combination strategies to improve targeted radionuclide therapy
US11590130B2 (en) Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer
CN103857395A (zh) Akt抑制剂化合物和阿比特龙的组合及使用方法
US11666574B2 (en) Combination therapy involving diaryl macrocyclic compounds
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN115768427A (zh) 癌症疗法中用于靶向降解不可靶向的kras的新型小分子
US11958867B2 (en) Alkyl amine dithiocarbamate gold complex for cancer treatment
WO2015112941A1 (fr) Nouvelles méthodes de traitement du cancer
Shen et al. Tumor cells and diseases related to drug treatment
US11981690B2 (en) Alkyl-terminated thiocarbamate complex and method for treating cancer
EP3804721A1 (fr) Agent antitumoral et méthode de traitement d'une tumeur
Gupta et al. A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics
Neuwelt et al. Silmitasertib. Casein kinase 2 (CK2) inhibitor, Treatment of solid and hematologic malignancies
CN114569619A (zh) Pi3k抑制剂单用或联合egfr抑制剂在制备治疗头颈癌或胃癌的药物中的用途
JP2014091711A (ja) Ｈｓｐ９０阻害剤と抗腫瘍性白金錯体との組み合わせ
JP2014034533A (ja) Ｈｓｐ９０阻害剤とｅｇｆｒチロシンキナーゼ阻害剤の組み合わせ

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19781419

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020551269

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3095709

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2019781419

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2019781419

Country of ref document: EP

Effective date: 20201105